⌘K
Loading ticker…
As of 2026-08-24, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a 3-month relative strength percentile of 3 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 24. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.8%, relative volume 0.92×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CVKD is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -35.6% / -73.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CVKD appears in 1 ETF as of Apr 2026: DFSU at 0.00% weight, $6K notional.
Held by 4 ETFs · $280K across latest filings · largest weight 0.00% (IWC).
Top 1 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DFSU | 0.00% | $6K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CVKD Jan avg: 38.10% median: 19.47% win: 75% σ: 77.23% n: 4 2023-01-23 → 2026-07-31 | CVKD Feb avg: -17.87% median: -16.16% win: 25% σ: 35.57% n: 4 2023-01-23 → 2026-07-31 | CVKD Mar avg: -22.35% median: -21.25% win: 0% σ: 14.80% n: 4 2023-01-23 → 2026-07-31 | CVKD Apr avg: -2.36% median: -5.91% win: 25% σ: 24.10% n: 4 2023-01-23 → 2026-07-31 | CVKD May avg: -7.84% median: -6.42% win: 50% σ: 16.85% n: 4 2023-01-23 → 2026-07-31 | CVKD Jun avg: -9.05% median: -4.94% win: 25% σ: 17.04% n: 4 2023-01-23 → 2026-07-31 | CVKD Jul avg: -26.17% median: -26.67% win: 0% σ: 18.23% n: 4 2023-01-23 → 2026-07-31 | CVKD Aug avg: 10.64% median: 16.95% win: 67% σ: 17.76% n: 3 2023-01-23 → 2026-07-31 (current) | CVKD Sep avg: 24.76% median: 6.71% win: 67% σ: 48.08% n: 3 2023-01-23 → 2026-07-31 | CVKD Oct avg: -4.03% median: -1.19% win: 33% σ: 29.80% n: 3 2023-01-23 → 2026-07-31 | CVKD Nov avg: -12.48% median: -10.44% win: 33% σ: 17.89% n: 3 2023-01-23 → 2026-07-31 | CVKD Dec avg: 9.49% median: -4.61% win: 33% σ: 45.96% n: 3 2023-01-23 → 2026-07-31 |